Since our founding in 2003, we have pursued our vision of using the immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. Our ultimate aim is to improve the lives of patients suffering from neurodegenerative diseases, by focusing on the root cause rather than symptom management: an ethos inspired by the impact that vaccines have on health and society worldwide. We have a broad portfolio of immunotherapy candidates which are currently in clinical trials or in preclinical development for a variety of neurodegenerative diseases; these include Parkinson’s disease (α-synuclein), Huntington’s disease (mutHTT), and Alzheimer’s disease (β-amyloid).
Meet our exceptional team, who have a proven track record of making ground-breaking scientific discoveries and developing novel therapies.
Together we can achieve more.
Before joining AFFiRiS, Oliver was a Managing Director at N M Rothschild & Sons Limited, London, UK between 2007 and 2014. In this role, he was responsible for the firm's pharmaceutical industry corporate finance activities in Europe. Oliver joined NM Rothschild & Sons Limited as a healthcare industry investment banker from HSBC, London, UK and Merrill Lynch Plc, London, UK. Oliver holds a master's degree in business administration from Otto Friedrich University, Bamberg, Germany.
Before joining AFFiRiS, he held various positions at Intercell and Biovertis AG, which he co-founded. Günther completed his doctorate degree in biochemistry and immunology at the Institute of Immunology, University of Vienna, Austria and has authored many publications in international journals. He was awarded the ‘Förderungspreis’ from the Austrian Society of Chemistry in 1996 and the ‘Fritz and Ursula Melchers Preis’ from the Austrian Society of Immunology in 2003.
Klaus is also Chairman of the Board of Directors at Anergis SA, Epalinges, Switzerland and Inthera Bioschiences AG, Wädenswil, Switzerland as well as member of the Supervisory Board of Apceth Biopharma GmbH, Munich, Germany.